Max A Mendez^1*, Andrej Besse^2*, Bogdan I. Florea^3*, Christian Zuppinger^4*, Herman S. Overkleeft^3*, Lenka Besse^5* and Christoph Driessen, MD⁵

¹Department of Oncology and Hematology, Laboratory of Experimental Oncology, St.Gallen Cantonal Hospital, St. Gallen, Switzerland
²Cantonal Hospital St Gallen, St Gallen, Switzerland
³Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
⁴Department for Biomedical Research, University of Bern, Bern, Switzerland
⁵Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland

Melissa Vrohlings^1*, Stephanie Jungmichel^1*, Jan Müller^2*, David Senn^1*, Thomas Schleier^1*, Fabian Scheifele^1*, Severin Wendelspiess^1*, Christian Leisner^1*, Maria-Theresa Krauth, MD^3*, Ulrich Jaeger, MD³ and Leonardo J. Borras^1*

¹CDR-Life, Schlieren, Switzerland
²Hematology, University Hospital Zurich, Zurich, Switzerland
³Dept. of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

Eugenio Morelli, MD^1,2, Mariateresa Fulciniti, PhD³, Mehmet K. Samur, PhD⁴, Caroline Ribeiro, PhD^5*, Leon Wert-Lamas, PhD^6*, Annamaria Gulla, MD⁷, Anil Aktas-Samur, PhD^3*, Katia Todoerti, PhD^8*, Srikanth Talluri, PhD^9,10*, Woojun Daniel Park¹¹, Jonathan E Henninger^12,13*, Cinzia Federico, PhD¹⁴, Giada Bianchi, MD¹⁵, Francesca Scionti, PhD^16*, Yao Yao^17*, Nicola Amodio, PhD^18*, Charles Y Lin, PhD^19*, Yu-Tzu Tai, PhD²⁰, Pierfrancesco Tassone, MD^16*, Antonino Neri, MD²¹, Dharminder Chauhan, PhD²², Teru Hideshima, MD, PhD²³, Richard A. Young, PhD^24,25*, Kenneth Anderson, MD²⁶, Carl D. Novina, MD, PhD⁶, Massimo Loda, MD^5* and Nikhil C. Munshi, MD^10,27

¹Department of Medical Oncology, DANA FARBER CANCER INSTITUTE, Boston, MA
²Harvard Medical School, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Weill Cornell Medical College, New York, NY
⁶Dana-Farber Cancer Institute, Boston, MA
⁷Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁸BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
⁹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, West Roxbury, MA
¹⁰VA Boston Healthcare System, Boston, MA
¹¹Baylor College of Medicine, Houston, TX
¹²Whitehead Institute of Biomedical Research, Massachusetts Institute of Technology (MIT), Cambridge, MA
¹³Biological and Biomedical Sciences Program, Harvard University, Cambridge, MA
¹⁴Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO
¹⁵Medical Oncology, Dana-Farber Cancer Insitute, Boston, MA
¹⁶Magna Graecia University, Catanzaro, Italy
¹⁷Dana Farber Cancer Institute, Boston, MA
¹⁸Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
¹⁹Dan L. Duncan Cancer Center, Department of Molecular and Human Genetics, Baylor College of Medicine, HOUSTON, TX
²⁰Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
²¹BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy
²²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²³Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁴Department of Biology, Massachusetts Institute of Technology, Cambridge, MA
²⁵Whitehead Institute for Biomedical Research, Cambridge, MA
²⁶Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Dongzheng Gai, MD^1*, Stewart JP^1*, Xuxing Shen^2*, Jin-Ran Chen, PhD^3*, Can Li, MD^1*, Bailu Peng, PhD^1*, Ya-Wei Qiang, MD, PhD¹, Shmuel Yaccoby, PhD¹, Maurizio Zangari, MD, FACP¹, Frits van Rhee, MD¹, Guido J. Tricot, MD, PhD¹, Lijuan Chen, MD, PhD^2*, John Shaughnessy Jr., PhD^1* and Fenghuang Zhan, MD, PhD¹

¹Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
²Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
³Arkansas Children’s Nutrition Center, Little Rock, AR

Chandraditya Chakraborty, PhD^1,2*, Yan Xu, MD^3,4,5*, Yao Yao^6,7*, Eugenio Morelli, MD^8,9,10, Anil Aktas-Samur, PhD^1,3,11,12*, Mehmet Kemal Samur, PhD^13,14*, Mariateresa Fulciniti, PhD^1,3,15, Nikhil C. Munshi, MD^{1,3,10,13,16,17,18,19,20,21,22,23,24}, Kenneth Anderson, MD^{2,3,8,10,13,15,19,20,21,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42}, Chandraditya Chakraborty, Ph D^1* and Sanika Derebail, MS^1*

¹Dana-Farber Cancer Institute, Boston, MA
²Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Institute of Hematology & Blood Diseases Hospital, Chinese Academic Medical Science & Peking Union Medical College, Tianjin, China
⁵dana-farber, Boston
⁶Dana Farber Cancer Institute, Boston, MA
⁷Dana-Farber Cancer Institute, boston, MA
⁸Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
⁹Department of Medical Oncology, DANA FARBER CANCER INSTITUTE, Boston, MA
¹⁰Harvard Medical School, Boston, MA
¹¹Department of Data Science, Dana Farber Cancer Institute, Boston, MA
¹²Harvard School of Public Health, Boston, MA
¹³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁴Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
¹⁵The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁶Boston VA Healthcare System, West Roxbury, MA
¹⁷VA Boston Healthcare System, Boston, MA
¹⁸The LeBow Institute for Myeloma Therapeutic and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁹Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁰Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²¹Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
²²Veterans Administration Boston Healthcare System, West Roxbury, MA
²³Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁴Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁵LeBow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁶Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Boston, MA
²⁷Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁸Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA
²⁹Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³⁰Blood Cancer Research Partnership, Boston, MA
³¹Dana–Farber Cancer Institute, Harvard Medical School, Boston
³²Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³³LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³⁴LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
³⁵LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³⁶Dana–Farber Cancer Institute, Boston, MA
³⁷Dana-Farber Cancer Institute/ Harvard Medical School, Boston, MA
³⁸Dana-Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA
³⁹Brigham and Women's Hospital, Boston, MA
⁴⁰Multiple Myeloma Research Consortium, Norwalk, CT
⁴¹The LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
⁴²The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Sophia Adamia, PhD¹, Shruti Bhatt, PhD², Yu-Tzu Tai, PhD¹, Kenneth Wen^3*, Catherine A Nicholas^4*, Marissa S Pioso^5*, Ivane Abiatari, MD^6*, Anthony G. Letai, MD, PhD⁷ and Kenneth Anderson, MD¹

¹Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Pharmacy, National University of Singapore, Singapore, Singapore
³Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
⁴Northeastern University and Dana-Farber Cancer Institute, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Institute of Medical and Public Health Research, Ilia State University, Tbilisi, Georgia
⁷Department of Medical Oncology, Dana-Farber Cancer Institute & HMS, Boston, MA

Konstantin Byrgazov, PhD^1*, Annica Rasmusson^2*, Claes Andersson^2*, Malin Berglund^2*, Lena Lenhammar^2*, Håkan Melhus^2*, Joachim Gullbo^2,3*, Ana Slipicevic^1*, Fredrik Lehmann^1*, Rolf Larsson^2*, Thomas Lind^2* and Mårten Fryknäs^2*

¹Oncopeptides AB, Stockholm, Sweden
²Department of Medical Sciences, Uppsala University, Uppsala, Sweden
³Theradex Oncology, Princeton, NJ

Shirong Li^1*, Jing Fu, PhD^1*, Jun Yang, MS^1*, Markus Y Mapara, MD, PhD², Christophe Marcireau^3* and Suzanne Lentzsch, MD, PhD¹

¹Division of Hematology and Oncology, Columbia University Medical Center, New York, NY
²Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
³Sanofi, Vitry sur seine, France